Industry context
Citius Oncology Inc [CTOR]
Last Updated 24 Jun 2026 @ 16:00 (Exchange is closed)
Last: $0.686
0.07%
-3.47 (↓)
GaG Algo Score™
v1.0
Short
-3.47 (↓)
Medium
-5.59 (↓)
Long
-5.42 (↓)
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 14.77% | 14.77% | 0.00% |
| Loss % | N/A | N/A | N/A |
| Duration | 14.0d | 14d | 0.0d |
| Total Pivots Found | 2 |
| Gain/Loss Legs | 1 (1 Gain / 0 Loss) |
| Last Pivot | Top @ $0.99 on 2026-05-13 |
| Change since Last Pivot | $-0.30 (-30.55%) |
Next Pivot Prediction Last: $0.69
| Predicted Next Type | N/A |
| Predicted Price (Avg) | N/A |
| Predicted Price (Median) | N/A |
| Predicted Price Range (~68%) | N/A |
| Change to Avg Target | N/A (N/A) |
| Predicted Date (Avg) | 2026-05-27 |
| Predicted Date Range (~68%) | 2026-05-27 - 2026-05-27 |
| Basis | Insufficient historical loss data for prediction. and duration (Avg: 14.0 days, StdDev: 0.0 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Slight gain for Citius Oncology Inc.
Citius Oncology Inc (CTOR) stock price remained flat on Wednesday after the stock rose $0.000500 (0.07%) from the previous session on below-average volume. The stock held up slightly better than the falling NASDAQ (-0.43% down). Yesterday's trading volume was 33 050 shares, worth about $22 656. This represents 7 418 shares more than the day before. Volume was below the 10-day average of 48 806 shares.
Citius Oncology Inc signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-46.7%), medium- (-46.7%), and long-term (-46.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Citius Oncology Inc Support & Resistance Levels
The stock is trading above the closest support level at $0.680. approximately $0.00550 (0.80%) away. This suggests it is currently acting as a floor, consolidating near support.The sup dis das support s10.68 -
Citius Oncology Inc Evaluation
- Short score: -3.47
- Medium score: -5.59
- Long score: -5.42
Ownership flow
GetAGraph InsiderPower
Transactions
58
Buy power
48.76M
Sell power
0
Reliability
100/100
Buy / sell
999.00
Hist. corr.
0.00
Latest signal
-
Director 32
Officer 24
Major holder 2
2025-09-19
Holubiak Myron Z Officer
Buy 850 000
2025-09-19
Holubiak Myron Z Officer
Buy 100 000
2025-09-19
Smith Robert Joseph Director
Buy 300 000
2025-09-19
Mazur Leonard L Officer
Buy 1 700 000
2025-09-19
Webb Carol Director
Buy 300 000
2025-09-19
Czuczman Myron Officer
Buy 825 000
Relationship map
Correlation snapshot
Positioning pressure
Short interest pressure
Short interest
0.75%
Of outstanding shares
Short float
13.83%
Of tradable float
Days to cover
9.59
Short interest divided by average volume
Squeeze probability
63.60%
+30.45% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
12
EPS beats
1
EPS misses
2
Avg. surprise
-21.53%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q1/2026 | 2025-05-14 | $-0.110 | $-0.0900 | -22.22% | - |
| Q4/2025 | 2025-02-14 | $-0.0900 | $-0.0600 | -50.00% | - |
| Q3/2025 | 2024-12-27 | $-0.0739 | $-0.0800 | 7.64% | - |
| Q2/2025 | 2024-09-30 | $-0.0739 | - | - | - |
| Q1/2025 | 2024-09-30 | $-0.0700 | - | - | - |
| Q4/2024 | 2024-09-30 | $-0.0700 | - | - | - |
| Q3/2024 | 2023-09-30 | $-0.0355 | - | - | - |
| Q2/2024 | 2023-09-30 | $-0.0355 | - | - | - |
Analyst view
Analyst targets
Consensus
$6.00
Median
$6.00
Low
$6.00
High
$6.00
Recent target updates
News flow
Latest company news
Market coverage
prnewswire.com Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Jun 1, 2026 prnewswire.com Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting May 26, 2026 prnewswire.com Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update May 15, 2026 prnewswire.com Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update May 15, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers General
Currency
USD
Citius Oncology Inc concentrates on advancing innovative targeted therapeutic solutions for various cancer types A key aspect of its pipeline includes the development of LYMPHIR an investigational orphan drug intended to treat adults battling cutaneous Tcell lymphoma that has either relapsed or is unresponsive to existing therapies The firms main offices are situated in New York New York Citius Oncology Inc functions as a division of its parent company Citius Pharmaceuticals Inc
Navigation